Sector News

EMA chief Rasi kicked out as tribunal annuls appointment

November 14, 2014
Life sciences
The European Medicines Agency’s executive director Guido Rasi has been forced to step down after his appointment, made three years, was annulled by a EU panel.
 
The European Union Civil Service Tribunal has ruled on an appeal by an individual against the selection procedure in 2011 for the appointment of executive director of the EMA. The unnamed person brought the case in January 2012 following the decision by the European Commission not to include him on the shortlist of candidates.
 
The court has, “on purely formal grounds”, annulled the Commission’s decision of adopting a shortlist and as a consequence, the choice of Dr Rasi (pictured) has also been annulled.
 
Sir Kent Woods, chair of the EMA management board, noted “with regret” the tribunal’s judgement, saying “it is important to remember that the ruling is about a procedural formality. It is not a reflection on Guido Rasi’s competence or ability to run the agency, something which he has done successfully since November 2011.”
 
The European Commission and EMA are both taking legal advice. “Pending further decisions”, Andreas Pott, the agency’s deputy executive director, will take over.
 
By Kevin Grogan
 
Source: Pharma Times
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]